Loading
journalsJournal
Journal of Nuclear Medicine
The Journal of Nuclear Medicine is the SNMMI's journal and the core venue for PET tracers and radioligand therapy: PSMA and somatostatin imaging, lutetium and actinium dosimetry, and theranostics trials.
Also called: JNMJ Nucl Med
Overview
The Journal of Nuclear Medicine appears monthly and publishes first-in-human tracer studies, PSMA PET diagnostic accuracy trials, radioligand-therapy dosimetry and outcomes (lutetium-177 PSMA and DOTATATE, actinium-225), and SNMMI procedure standards. Articles become free to read after a delay; the SNMMI annual meeting abstracts are published as a supplement.
Publisher
Society of Nuclear Medicine and Molecular Imaging · Society of Nuclear Medicine and Molecular Imaging
Scope
nuclear medicine
Website
Access model
hybrid
Founded
1960
ISSN
0161-5505
observational202413 citations
First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
This is the paper Europe PMC returns for registry id NCT05413850 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observational2022143 citations
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
basic20191,130 citations
68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational2019changed practice213 citations
Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma
Radionuclide therapy is a standard option for MIBG-avid metastatic pheochromocytoma and paraganglioma; somatostatin receptor targeted lutetium therapy is the alternative for SSTR-avid disease.
observational2019470 citations
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational201898 citations
Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Clemens Kratochwil
Nuclear medicine physician, Heidelberg University Hospital
Targeted alpha therapyPSMA radioligandsDosimetry
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Frederik Giesel
Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg
Molecular imagingFAPI PETPSMA theranostics
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Jason S. Lewis
Emily Tow Jackson Chair in Oncology and Chief Attending, Radiochemistry and Imaging Sciences Service, Memorial Sloan Kettering Cancer Center
RadiochemistryImmuno-PETRadiopharmaceutical development
Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.
Jeremie Calais
Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA
PSMA PETRadioligand therapyClinical trials
Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.
Richard P. Baum
Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt
Nuclear medicinePeptide receptor radionuclide therapyPSMA radioligand therapy
One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.
Uwe Haberkorn
Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ
Nuclear medicineFAP-targeted radiopharmaceuticalsTheranostics
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
observationalJournal of Nuclear Medicine 202413 citations
First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
This is the paper Europe PMC returns for registry id NCT05413850 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observationalJournal of Nuclear Medicine 2022143 citations
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
basicJournal of Nuclear Medicine 20191,130 citations
68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalJournal of Nuclear Medicine 2019changed practice213 citations
Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma
Radionuclide therapy is a standard option for MIBG-avid metastatic pheochromocytoma and paraganglioma; somatostatin receptor targeted lutetium therapy is the alternative for SSTR-avid disease.
observationalJournal of Nuclear Medicine 2019470 citations
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalJournal of Nuclear Medicine 201898 citations
Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Similar pages
- InstitutionEuropean Association of Nuclear Medicine
Shares Clemens Kratochwil, Frederik Giesel, Uwe Haberkorn, Radioligand therapy (beta emitters).
- TrialAnti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Shares First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer, Radioligand therapy (beta emitters).
- IdeaA university cyclotron network with shared regulatory files for new tracers
Shares Frederik Giesel, Uwe Haberkorn, Radioligand therapy (beta emitters).
- TechnologyNuclear medicine and total-body PET hardware
Shares First Human Imaging Studies with the EXPLORER Total-Body PET Scanner, Radioligand therapy (beta emitters).
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares 68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer, Radioligand therapy (beta emitters).
- InstitutionSociety of Nuclear Medicine and Molecular Imaging
Shares SNMMI Annual Meeting, Radioligand therapy (beta emitters).
- InstitutionHeidelberg University Hospital / NCT / DKFZ
Shares Clemens Kratochwil, Frederik Giesel, Uwe Haberkorn.
- Treatment131I-MIBG (iobenguane I-131) therapy
Shares Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma, Radioligand therapy (beta emitters).
technologies
collections
people
key papers
68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerBiodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine MalignanciesCD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyEfficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paragangliomaFirst Human Imaging Studies with the EXPLORER Total-Body PET ScannerFirst Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer